SK Bioscience Co.,Ltd
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
As of 2026-10-10, SK Bioscience Co.,Ltd has 18 Korean MFDS drug approvals, 55 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEstablished in 2018 through a spin-off of SK Chemicals' vaccine division and listed on KOSPI in 2021, SK Bioscience is a vaccine-focused company. It has developed in-house vaccines including the cell-culture flu vaccines SKYCellflu and SKYCellflu4, the shingles vaccine SKYZoster, the varicella vaccine SKYVaricella, the typhoid conjugate vaccine SKYTyphoid, and the COVID-19 vaccine SKYCovione, while also serving as CDMO for AstraZeneca's Vaxzevria and Novavax's Nuvaxovid. Under a 2014 co-development agreement with Sanofi worth US$45.0M plus EUR350M, it is running a global Phase 3 trial of a 21-valent pneumococcal vaccine in about 9,000 children and adolescents, and has a US$140.0M agreement with CEPI covering the mRNA-based Japanese encephalitis vaccine GBP560.
Products & technology
- SKYCellfluCell-culture trivalent influenza vaccine
- SKYCellflu4Cell-culture quadrivalent influenza vaccine
- SKYZosterShingles vaccine
- SKYVaricellaVaricella vaccine
- SKYTyphoidTyphoid conjugate vaccine
- SKYCovioneCOVID-19 vaccine (GBP510)
Regulatory approvals
data.go.kr18 Korean MFDS drug approvals · 1998–2022
- MFDS drugSkyCovione Multi Injection2022-06-29Drug · Prescription · Approval202202677
- MFDS drugSKYTyphoid multi inj. (Thyphoid purified Vi Polysaccharide Conjugated to Diphtheria toxoid vaccine)2022-05-12Drug · Prescription · Approval202201983
- MFDS drugNUVAXOVID Pre-filled syringe (SARS-CoV-2 Spike Protein Vaccine(Recombinant))2022-01-12Drug · Prescription · Approval202200228
- MFDS drugSKYPneumo Prefilled syringe (Pneumococcal Polysaccharide Conjugated to Diphtheria CRM 197)2021-06-04Drug · Prescription · Approval202104391
- MFDS drugSKYPneumo Prefilled syringe (for export)Revoked2020-05-14Drug · Prescription · Approval202003491
- MFDS drugSKYCellflu Prefilled Syringe (for export)2020-01-10Drug · Prescription · Approval202000160
- MFDS drugSKYCellflu Quadrivalent Prefilled Syringe (0.5mL) (for export)2020-01-09Drug · Prescription · Approval202000155
- MFDS drugSKYCellflu Quadrivalent Multi inj. (surface antigen, inactivated, prepared in cell culture) (for export)2019-02-22Drug · Prescription · Approval201901145
- MFDS drugSKYCellflu Quadrivalent inj. (surface antigen, inactivated, prepared in cell culture) (for export)2019-02-18Drug · Prescription · Approval201900985
- MFDS drugSKYVaricella Inj. (Varicella Virus Vaccine (live) [Oka/SK])2018-06-04Drug · Prescription · Approval201802323
- MFDS drugSKYZoster Vaccine Inj. (Zoster Virus Vaccine (live) [Oka/SK])2017-09-29Drug · Prescription · Approval201707343
- MFDS drugSKYCellflu®Multi inj. (Trivalent Influenza Vaccine) (for export)2017-09-06Drug · Prescription · Approval201706967
Show 6 more
- MFDS drugSKYCellflu®inj. (Trivalent Influenza Vaccine) (for export)2017-03-27Drug · Prescription · Approval201701434
- MFDS drugSKYCellflu Quadrivalent Prefilled Syringe (Surface Antigen, Inactivated, prepared in cell culture)2015-12-24Drug · Prescription · Approval201508425
- MFDS drugSKYCellflu Prefilled Syringe (Surface Antigen, Inactivated, prepared in cell culture)2014-12-26Drug · Prescription · Approval201406070
- MFDS drugHepamun Prefilled Syringe (Hepatitis B Vaccine(rDNA))2012-04-24Drug · Prescription · Approval201203144
- MFDS drugSK Td Vaccine Inj. (Pre-filled Syringe) (Adsorbed Diphtheria-Tetanus combined Toxoid for adult)Revoked2005-02-28Drug · Prescription · Approval200501774
- MFDS drugHepamune Inj. (Hepatitis B Vaccine, recombinant)Revoked1998-11-10Drug · Prescription · Approval199801806
Clinical trials
data.go.kr8 MFDS clinical trial authorisations · 2016–2025 (Phase 3 4 · Phase 1 2 · Phase 1/2 2)
- Phase 3스카이바리셀라주(NBP608)2025-12-16
10 trial sites
- Phase 1NBP18012025-04-14
1 trial site
- Phase 3GBP5102021-08-10
19 trial sites
- Phase 1/2GBP5102021-01-26
15 trial sites
- Phase 1/2GBP5102020-12-31
15 trial sites
- Phase 1NBP20012020-11-23
3 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2018-08-31
12 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2016-10-06
12 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 3 · Recruiting · 2026-07 · NCT07415252
Phase 1/2 · Active not recruiting · 2026-01 · NCT07280858
Phase 1/2 · Completed · 2025-02 · NCT06680128
Withdrawn · 2023-02 · NCT05710289
Phase 3 · Completed · 2022-12 · NCT05501522
Phase 3 · Completed · 2021-08 · NCT05007951
Phase 1/2 · Unknown · 2021-02 · NCT04750343
Phase 1/2 · Completed · 2021-01 · NCT04742738
Phase 1 · Completed · 2020-12 · NCT04760743
Phase 1/2 · Completed · 2018-12 · NCT04453241
Show 2 more trials
Phase 3 · Completed · 2018-10 · NCT03704740
Phase 3 · Completed · 2016-07 · NCT03114943
R&D and key agreements
Source: DART corporate disclosure21가 폐렴구균백신(GBP410) · 폐렴구균 감염증 · 글로벌 임상 3상 · Co-developed with Sanofi since 2014; Phase 3 in ~9,000 children/adolescents from Dec 2024
차세대 폐렴구균백신(NextGen) · 폐렴구균 감염증 · 기초연구/비임상 · Expanded co-development deal with Sanofi (2024)
일본뇌염 mRNA백신(GBP560) · 일본뇌염 · 글로벌 임상 1/2상(2025~) · Co-developed with CEPI since 2022
라싸열 mRNA백신(GBP570) · 라싸열 · 기초연구 · Co-developed with CEPI
범용 사베코바이러스백신(GBP511) · 사베코바이러스 감염증 · 임상 1/2상 IND 승인 · CEPI agreement, Dec 2021, US$65.1M
Nasal Spray 백신 · 임상시료 생산완료/안정성시험 진행중 · IAVI agreement, Nov 2021, US$4M
Key disclosures
KRX KIND via OpenDARTShow 9 more events
Publications
PubMed · affiliation-matched- Sequence-Aware Antigenic Alignment and SRID Potency Interpretation in Influenza Vaccines.
Vaccine · 2026-10 · Jeong O, Kim PK, Oh H 외 2
- Scalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coli.
Pharmaceutics · 2026-09 · Shin J, Kim EM, Jang JH 외 12
- Topical application of Cas9 ribonucleoproteins inhibits corneal neovascularization in a mouse model of alkali burn injury.
Gene therapy · 2026-07 · Lee SJ, Nam BG, Hong SA 외 4
- Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial.
Vaccines · 2026-04 · Yoon Y, Cho HK, Kim KH 외 13
- Post-Marketing Surveillance Study of the Live Attenuated Varicella Vaccine (SKYVaricella Inj.) in Korean Children.
Infection & chemotherapy · 2026-03 · Kim H, Kim K, Kim HY
- Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay.
Vaccine · 2026-03 · Jeong O, Choi W, Ahn H 외 4
- Influenza Vaccine Effectiveness in Korea: A Systematic Review and Meta-Analysis of Real-World Evidence from the Past Decade.
Vaccines · 2026-02 · Jeong HS, Kim HY
- Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine (SKYCellflu® QIV) in Children and Adolescents: A Multicenter Test-Negative Case-Control Study in Korea.
Vaccines · 2026-01 · Yoon Y, Jeong HS, Oh K 외 5
- Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026-01 · Song JY, Choi WS, Heo JY 외 24
- Reply: Exploring a More Accessible and Affordable Live Attenuated Herpes Zoster Vaccine (SKYZoster®) in the Philippines.
Infection & chemotherapy · 2025-12 · Baik SH, Kim HY
Show 45 more publications
- Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants.
The Pediatric infectious disease journal · 2025-10 · Pichon S, Ullery GM, Cousin L 외 10
- Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.
Vaccine · 2025-10 · Pial RH, Capeding MR, Tadesse BT 외 20
- TXNIP Suppresses Lung Cancer Progression by Inhibiting TRAF6-Mediated NF-κB Activation and Autophagy.
Immune network · 2025-10 · Kim JY, Kim MJ, Shin JH 외 10
- Post-marketing Surveillance of a Live Attenuated Herpes Zoster Vaccine (SKYZoster®) in Adults Aged ≥50 Years in Korea.
Infection & chemotherapy · 2025-09 · Baik SH, Lee H, Kim H 외 1
- Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.
Vaccine · 2025-07 · Pial RH, Capeding MR, Song KR 외 18
- Safety and Influenza Infections in Children Aged 6-35 Months Receiving Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine During the 2023-2024 Influenza Season in South Korea.
Vaccines · 2025-05 · Lee HE, Park SB, Kim HY 외 4
- Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines.
bioRxiv : the preprint server for biology · 2025-05 · Addetia A, Schäfer A, Sprouse K 외 30
- Re: 'Heightened incidence of adverse events associated with a live attenuated varicella vaccine strain that lacks critical genetic polymorphisms in ORF62' by Kim et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2025-03 · Han YW, Hong SH, Kang SG 외 2
- The Importance of Accurate Communication for Public Health Benefits and Commitment to Safety Monitoring.
Journal of medical virology · 2025-03 · Kang SG, Kim HY
- Letter to the Editor: Clarification of Evidence and Consensus on Strengthening Pharmacovigilance for Vaccine Safety.
Journal of Korean medical science · 2024-12 · Kim HY
- Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection.
Vaccines · 2024-12 · Kang KR, Kim PK, Jo KM 외 3
- A booster administration of the OKA/SK strain causes fatal disseminated varicella in an immunocompetent child.
Journal of medical virology · 2024-07 · Park SB, Lee SJ, Kim HY
- Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea.
Journal of Korean medical science · 2024-06 · Ryu JH, Choi A, Woo J 외 4
- Adjustment to "new normal" after cancer among non-small cell lung cancer survivors: A qualitative study.
Palliative & supportive care · 2024-06 · Lee G, Kim SY, Ahn A 외 8
- Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Vaccine · 2024-01 · Park SI, Park S, Lee K 외 19
- The Adenylyl Cyclase Activator Forskolin Increases Influenza Virus Propagation in MDCK Cells by Regulating ERK1/2 Activity.
Journal of microbiology and biotechnology · 2023-12 · Lee SY, Lee J, Park HL 외 3
- Corrigendum to "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants" [Vaccine 41(11) (2023) 1892-1901].
Vaccine · 2023-11 · Kwak HW, Park HJ, Jung SY 외 24
- Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial.
EClinicalMedicine · 2023-10 · Song JY, Choi WS, Heo JY 외 27
- Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study.
Vaccines · 2023-08 · Choi UY, Kim KH, Cho HK 외 11
- Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
Vaccine · 2023-03 · Kwak HW, Park HJ, Jung SY 외 24
- Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques.
NPJ vaccines · 2023-02 · Jacob-Dolan C, Yu J, McMahan K 외 21
- Single-stranded RNA adjuvant enhances the efficacy of 10-valent human papilloma virus-like particle vaccine.
Microbiology and immunology · 2022-11 · Kwak HW, Shin W, Baik K 외 12
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
EClinicalMedicine · 2022-09 · Song JY, Choi WS, Heo JY 외 27
- Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
Vaccine · 2022-09 · Saluja T, Rai GK, Chaudhary S 외 20
- A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
The Lancet regional health. Western Pacific · 2022-07 · Carlos JC, Tadesse BT, Borja-Tabora C 외 20
- Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
The Lancet. Infectious diseases · 2022-04 · Kumar Rai G, Saluja T, Chaudhary S 외 23
- Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
NPJ vaccines · 2022-01 · Capeding MR, Tadesse BT, Sil A 외 17
- Influenza vaccines: Past, present, and future.
Reviews in medical virology · 2022-01 · Kim YH, Hong KJ, Kim H 외 1
- White adipocyte-targeted dual gene silencing of FABP4/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes.
Biomaterials · 2021-12 · Chung JY, Hong J, Kim HJ 외 4
- Iron Metabolism as a Potential Mechanism for Inducing TRAIL-Mediated Extrinsic Apoptosis Using Methylsulfonylmethane in Embryonic Cancer Stem Cells.
Cells · 2021-10 · Sp N, Kang DY, Jo ES 외 2
- Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant.
Scientific reports · 2021-06 · Bang YJ, Hong SH, Park HJ 외 14
- Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.
Science advances · 2021-05 · Hong SH, Oh H, Park YW 외 33
- Pivotal Role of Iron Homeostasis in the Induction of Mitochondrial Apoptosis by 6-Gingerol Through PTEN Regulated PD-L1 Expression in Embryonic Cancer Cells.
Frontiers in oncology · 2021-01 · Sp N, Kang DY, Jo ES 외 3
- Assignment of opsonic values to pneumococcal reference serum 007sp and a second pneumococcal OPA calibration serum panel (Ewha QC sera panel B) for 11 serotypes.
Vaccine · 2020-12 · Burton RL, Kim HW, Lee S 외 13
- Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
EClinicalMedicine · 2020-10 · Capeding MR, Sil A, Tadesse BT 외 22
- Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
Vaccine · 2020-09 · Kim YH, Bang YJ, Park HJ 외 5
- Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial.
Clinical and experimental pediatrics · 2020-07 · Shin J, Teeratakulpisarn J, Puthanakit T 외 7
- Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Vaccine · 2020-06 · Capeding MR, Alberto E, Sil A 외 18
- Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
Immunity, inflammation and disease · 2020-06 · Lee SJ, Park HJ, Ko HL 외 4
- WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019.
Biologicals : journal of the International Association of Biological Standardization · 2020-05 · Wadhwa M, Kang HN, Jivapaisarnpong T 외 55
- Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
PLoS neglected tropical diseases · 2020-03 · Lee EY, Park JY, Kim DR 외 5
- Comparison of antigenic mutation during egg and cell passage cultivation of H3N2 influenza virus.
Clinical and experimental vaccine research · 2020-01 · Park YW, Kim YH, Jung HU 외 4
- A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age.
The Pediatric infectious disease journal · 2019-09 · Eun BW, Lee TJ, Lee J 외 7
- Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.
Vaccine · 2019-08 · Kwak HW, Park HJ, Ko HL 외 13
- Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
Vaccine · 2019-06 · Choi WS, Choi JH, Jung DS 외 8
Patents
KIPRIS · applicant-matchedPCT · Published · 2026-01 · Application PCT/KR2026/001039
Published · 2026-01 · Application 1020260009268
US · Published · 2025-09 · Application 19329754
Published · 2025-03 · Application 1020250036064
PCT · Published · 2025-03 · Application PCT/KR2025/003212
US · Published · 2025-03 · Application 19074708
Published · 2024-12 · Application 1020240197704
Published · 2024-12 · Application 1020240195777
PCT · Published · 2024-12 · Application PCT/KR2024/096904
Published · 2024-12 · Application 1020240185648
Show 183 more patents
PCT · Published · 2024-11 · Application PCT/KR2024/017554
US · Published · 2024-10 · Application 18932238
Published · 2024-10 · Application 1020240147899
Published · 2024-09 · Application 1020240125387
US · Published · 2024-08 · Application 18800657
Registered · 2024-08 · Application 1020240107920
PCT · Published · 2024-07 · Application PCT/KR2024/009542
Published · 2024-07 · Application 1020240088676
EP · Published · 2024-03 · Application 24781312.4
PCT · Published · 2024-03 · Application PCT/KR2024/004079
Published · 2024-03 · Application 1020240043423
US · Registered · 2024-03 · Application 18598439
US · Registered · 2024-01 · Application 18419900
Registered · 2023-12 · Application 1020230187025
Published · 2023-12 · Application 1020230181155
Published · 2023-10 · Application 1020230148452
US · Published · 2023-07 · Application 18993863
EP · Published · 2023-07 · Application 23840034.5
PCT · Published · 2023-07 · Application PCT/KR2023/095028
Registered · 2023-07 · Application 1020230090668
Registered · 2023-05 · Application 1020230057790
US · Published · 2023-04 · Application 18860888
EP · Published · 2023-04 · Application 23796815.1
PCT · Published · 2023-04 · Application PCT/KR2023/005736
Published · 2023-04 · Application 1020230055597
CN · Published · 2023-04 · Application 202380041892.7
US · Published · 2023-04 · Application 18858857
EP · Published · 2023-04 · Application 23792262.0
PCT · Published · 2023-04 · Application PCT/KR2023/005580
Registered · 2023-04 · Application 1020230053644
Published · 2023-04 · Application 1020230048765
Registered · 2023-01 · Application 1020230009232
EP · Published · 2023-01 · Application 23747272.5
US · Published · 2023-01 · Application 18730572
PCT · Published · 2023-01 · Application PCT/KR2023/001035
Published · 2023-01 · Application 1020230008810
Withdrawn · 2022-12 · Application 1020220186401
Registered · 2022-12 · Application 1020220183757
PCT · Published · 2022-11 · Application PCT/KR2022/017256
PCT · Published · 2022-10 · Application PCT/KR2022/015664
Registered · 2022-10 · Application 1020220132698
Registered · 2022-10 · Application 1020220132531
CN · Published · 2022-09 · Application 202280075682.5
US · Published · 2022-09 · Application 18696130
EP · Published · 2022-09 · Application 22876926.1
PCT · Published · 2022-09 · Application PCT/KR2022/014712
Published · 2022-09 · Application 1020220124746
PCT · Published · 2022-09 · Application PCT/KR2022/014352
US · Published · 2022-08 · Application 18294013
EP · Published · 2022-08 · Application 22858727.5
PCT · Published · 2022-08 · Application PCT/KR2022/012233
Registered · 2022-08 · Application 1020220102797
CN · Published · 2022-07 · Application 202280046529.X
US · Published · 2022-07 · Application 18291888
EP · Published · 2022-07 · Application 22849769.9
PCT · Published · 2022-07 · Application PCT/KR2022/010285
Registered · 2022-07 · Application 1020220086988
CN · Published · 2022-06 · Application 202280060199.X
US · Published · 2022-06 · Application 18576816
EP · Published · 2022-06 · Application 22837864.2
PCT · Published · 2022-06 · Application PCT/KR2022/009016
Registered · 2022-06 · Application 1020220077781
Withdrawn · 2022-05 · Application 1020220066095
CN · Published · 2022-03 · Application 202280038675.8
US · Published · 2022-03 · Application 18562030
EP · Published · 2022-03 · Application 22816270.7
PCT · Published · 2022-03 · Application PCT/KR2022/004186
PCT · Published · 2022-03 · Application PCT/KR2022/004185
Registered · 2022-03 · Application 1020220030768
CN · Published · 2022-01 · Application 202280030562.3
US · Published · 2022-01 · Application 18278925
EP · Published · 2022-01 · Application 22759922.2
PCT · Published · 2022-01 · Application PCT/KR2022/001307
Registered · 2021-12 · Application 1020210188322
Rejected · 2021-12 · Application 1020210187185
Withdrawn · 2021-12 · Application 1020210187493
Registered · 2021-12 · Application 1020210180825
Registered · 2021-12 · Application 1020210179185
Registered · 2021-11 · Application 1020210167438
PCT · Published · 2021-10 · Application PCT/KR2021/015484
Rejected · 2021-10 · Application 1020210147356
US · Registered · 2021-10 · Application 18034141
EP · Published · 2021-10 · Application 21886822.2
PCT · Published · 2021-10 · Application PCT/KR2021/015262
Registered · 2021-10 · Application 1020210145047
PCT · Published · 2021-10 · Application PCT/KR2021/015139
CN · Published · 2021-10 · Application 202180086540.4
US · Published · 2021-10 · Application 18033319
EP · Published · 2021-10 · Application 21883367.1
Published · 2021-10 · Application 1020210142198
US · Published · 2021-10 · Application 17500716
Rejected · 2021-10 · Application 1020210131141
PCT · Published · 2021-09 · Application PCT/KR2021/012981
Withdrawn · 2021-09 · Application 1020210125995
Registered · 2021-09 · Application 1020210125225
Registered · 2021-08 · Application 1020210104353
Registered · 2021-07 · Application 1020210095029
Registered · 2021-07 · Application 1020210088575
Registered · 2021-05 · Application 1020210070036
TW · Registered · 2021-04 · Application 110115498
US · Published · 2021-04 · Application 17922407
EP · Published · 2021-04 · Application 21796754.6
PCT · Published · 2021-04 · Application PCT/KR2021/005488
Registered · 2021-04 · Application 1020210055290
US · Published · 2021-04 · Application 17922262
EP · Published · 2021-04 · Application 21796985.6
PCT · Published · 2021-04 · Application PCT/KR2021/004356
Registered · 2021-02 · Application 1020210026617
Registered · 2021-02 · Application 1020210019125
CN · Published · 2020-12 · Application 202080096843.X
US · Registered · 2020-12 · Application 17787925
EP · Published · 2020-12 · Application 20901031.3
PCT · Published · 2020-12 · Application PCT/KR2020/018703
Registered · 2020-12 · Application 1020200172526
CN · Published · 2020-11 · Application 202080082143.5
EP · Published · 2020-11 · Application 20893843.1
Withdrawn · 2020-10 · Application 1020200143421
Withdrawn · 2020-09 · Application 1020200121713
- Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
TW · Published · 2020-07 · Application 114124117
- Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
TW · Published · 2020-07 · Application 109125637
CN · Published · 2020-07 · Application 202080061473.6
- MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITIONS AND METHODS OF USING THE SAME
US · Published · 2020-07 · Application 17630841
- MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITIONS AND METHODS OF USING THE SAME
EP · Published · 2020-07 · Application 20754563.3
- MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITIONS AND METHODS OF USING THE SAME
PCT · Published · 2020-07 · Application PCT/US2020/043729
Published · 2020-07 · Application 1020227004904
Registered · 2020-04 · Application 1020200052700
Registered · 2020-04 · Application 1020200052708
US · Registered · 2020-02 · Application 17429089
EP · Published · 2020-02 · Application 20752212.9
Registered · 2019-11 · Application 1020190154749
CN · Published · 2019-11 · Application 201980087400.1
US · Registered · 2019-11 · Application 17290384
EP · Published · 2019-11 · Application 19877972.0
PCT · Published · 2019-11 · Application PCT/KR2019/014755
CN · Published · 2019-10 · Application 201980073535.2
US · Published · 2019-10 · Application 17283658
EP · Published · 2019-10 · Application 19870535.2
Registered · 2019-10 · Application 1020190127265
Registered · 2019-05 · Application 1020190062757
Registered · 2019-05 · Application 1020190062794
Withdrawn · 2019-05 · Application 1020190052553
CN · Published · 2019-04 · Application 201980026186.9
TW · Published · 2019-04 · Application 108113678
US · Registered · 2019-04 · Application 17047563
EP · Published · 2019-04 · Application 19788873.8
PCT · Published · 2019-04 · Application PCT/KR2019/004717
Withdrawn · 2019-04 · Application 1020190045589
TW · Registered · 2019-02 · Application 108104495
TW · Registered · 2019-02 · Application 108104493
TW · Registered · 2019-02 · Application 112144714
Rejected · 2019-02 · Application 1020190014539
CN · Published · 2019-02 · Application 201980009513.X
CN · Published · 2019-02 · Application 202411035063.0
CN · Published · 2019-02 · Application 201980011404.1
US · Registered · 2019-02 · Application 16966552
US · Registered · 2019-02 · Application 16966584
EP · Published · 2019-02 · Application 19748037.9
EP · Published · 2019-02 · Application 19747393.7
Published · 2019-02 · Application 1020237000531
Registered · 2019-02 · Application 1020207025714
Registered · 2019-02 · Application 1020207025716
Registered · 2018-11 · Application 1020180133084
PCT · Published · 2018-09 · Application PCT/KR2018/011324
Registered · 2018-09 · Application 1020180113291
CN · Published · 2018-07 · Application 201880016526.5
US · Registered · 2018-07 · Application 16628228
Rejected · 2017-11 · Application 1020170156624
TW · Registered · 2017-08 · Application 106126432
TW · Registered · 2017-08 · Application 106126433
US · Registered · 2017-08 · Application 16322698
EP · Registered · 2017-08 · Application 17837752.9
EP · Registered · 2017-08 · Application 17837755.2
Registered · 2017-08 · Application 1020197004330
Registered · 2017-08 · Application 1020197004332
Registered · 2017-07 · Application 1020170085472
Registered · 2016-07 · Application 1020160094118
EP · Registered · 2013-12 · Application 13862717.9
EP · Registered · 2013-12 · Application 13862871.4
Registered · 2013-09 · Application 1020130106993
EP · Registered · 2013-06 · Application 13806263.3
Rejected · 2012-12 · Application 1020120143318
Rejected · 2012-12 · Application 1020120143310
Registered · 2012-06 · Application 1020120065893
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot202
- GoogleGoogleOther45
- PerplexityPerplexityBot9
- MicrosoftBingbot2
- AnthropicClaudeBot2
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SK Bioscience Co.,Ltd and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition